Profile
ACHL NVO VRTX REGN MRNA SGEN
Company Name Achilles Therapeutics plc Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $38.63M $563.06B $109.10B $105.53B $44.96B $43.15B
Employees 0.20K 66.02K 5.40K 13.68K 5.60K 3.26K
CEO Dr. Iraj Ali Ph.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
ACHL NVO VRTX REGN MRNA SGEN
Quant Rating Score 2 5 5 5 2 3
Quant Rating Sell Strong Buy Strong Buy Strong Buy Sell Neutral
Trading
ACHL NVO VRTX REGN MRNA SGEN
Last Close $0.9401 $128.42 $422.78 $973.8 $117.31 $228.74
High 52 $1.57 $199.54 $446.08 $993.35 $137.75 $228.9
Low 52 $0.75 $87.78 $323.57 $692.45 $69.51 $187.64
Price vs. 52 Week High -40.12 % -35.64 % -5.22 % -1.97 % -14.84 % -0.07 %
Price vs. 52 Week Low 25.35 % 46.3 % 30.66 % 40.63 % 68.77 % 21.9 %
Total Return
ACHL NVO VRTX REGN MRNA SGEN
1 Month Return 10.6 % 2.41 % 5.63 % 5.81 % 9.63 % 0 %
3 Month Return 0.01 % 5.96 % -0.03 % 2.14 % 34.21 % 0 %
6 Month Return 17.51 % 26.91 % 13.15 % 21.89 % 67.47 % 7.03 %
9 Month Return -5.04 % -29.28 % 20.84 % 20.68 % 15.59 % 17.5 %
YTD Return 5.75 % 24.14 % 3.91 % 10.87 % 17.96 % 0 %
1 Year Return -1.35 % -24.01 % 20.66 % 30.61 % -8.64 % 14.66 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL NVO VRTX REGN MRNA SGEN
Dividend Yield Percentage (TTM) - 0.16 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -122.12 % 1.1 % 13.85 % 6.2 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
ACHL NVO VRTX REGN MRNA SGEN
Asset Growth -26.73 % 30.35 % 25.23 % 13.23 % -28.74 % -1.21 %
Gross Profit Growth -28.3 % 32.32 % 9.25 % 6.49 % -85.12 % 22.93 %
Revenue Growth - 31.26 % 10.17 % 7.76 % -64.94 % 24.65 %
Revenue 3 Year - 90.51 % 59.87 % 55.67 % 2356.27 % 91.84 %
Revenue 5 Year - 124.2 % 218.58 % 110.3 % 1070.62 % 215.48 %
Revenue 10 Year - 66.11 % 608.27 % 549.62 % 6447.35 % 494.04 %
EBIT Growth -8.42 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Net Income Growth 1.74 % 50.71 % 8.96 % -8.87 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share -114.07 % 106.79 % 34.59 % 13.48 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share 79.47 % 133.86 % 70.33 % 74.02 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share 79.47 % 98.61 % 809.6 % 871.12 % -2046.03 % -624.16 %
Operating Income Growth -8.42 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) 18.31 % 38.06 % -14.35 % -8.39 % -162.6 % 9.07 %
Operating 3 Year CFG -95.73 % 118.29 % 9.63 % 76.95 % -253.56 % -148.34 %
Operating 5 Year CFG 85.87 % 163.51 % 174.78 % 125.17 % -100.11 % -195.86 %
Operating 10 Year CFG 85.87 % 150.92 % 5187.08 % 713.56 % -4698.89 % -2622.09 %
EPS Growth 3.85 % 52.28 % 8.33 % -8.54 % -158.15 % 10.81 %
EPS Diluted Growth 3.85 % 52.37 % 8.35 % -9.03 % -161.39 % 10.81 %
Book Value Per Share -29.25 % 29 % 25.58 % 15.03 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -23.6 % 75.22 % 104.06 % 137.56 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share -94.23 % 121.9 % 291.14 % 219.1 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -94.23 % 49.62 % 1030.79 % 1286.9 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -46.19 % 4.74 % 44.1 % 0.06 % 3.58 % -23.28 %
Free Cash Flow Growth 25.81 % 9.17 % -16.47 % -17.11 % -183.5 % 3.67 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
ACHL NVO VRTX REGN MRNA SGEN
Gross Profit Margin TTM - 84.65 % 86.91 % 87.16 % 21.77 % 75.4 %
Return on Assets TTM -43.25 % 29.87 % 16.81 % 11.22 % -35.67 % -20.64 %
Return on Equity TTM -42.65 % 91.82 % 23.61 % 15.15 % -41.83 % -28.06 %
Return on Capital Employed TTM -52.21 % 82.5 % 21.07 % 12.53 % -35.81 % -29.5 %
Net Income Per EBT TTM 100.71 % 79.81 % 84.31 % 95.44 % 124.28 % 101.53 %
EBT Per Ebit TTM 91.92 % 101.7 % 112.45 % 104.74 % 93.44 % 93.47 %
EBIT Per Revenue TTM - 45.03 % 41.62 % 29.46 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM -285.74 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Receivables Turnover TTM - 3.87 5.68 2.51 13.32 3.64
Payables Turnover TTM 0.65 2.88 0.42 2.51 22.04 2.52
Inventory Turnover TTM 3659178 1.12 1.64 0.62 13.67 1.07
Fixed Asset Turnover TTM - 248.64 % 685.54 % 310.02 % 186.78 % 471.71 %
Asset Turnover TTM - 81.71 % 42.58 % 38.12 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -0.33 20.95 15.27 43.96 -7.54 -2.87
Free Cash Flow Per Share TTM -0.33 11.28 14.17 36.87 -9.61 -3.73
Cash Per Share TTM 327.32 % 208.61 % 3939.31 % 9758.35 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM - 38.24 % 38.72 % 36.17 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.82 % 53.85 % 92.78 % 83.87 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM -285.74 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM -2.91 77.52 29.81 26.55 -12.24 -61.54
Price To Operating Cash Flows Ratio TTM -2.86 42.47 27.68 22.15 -15.55 -79.67
Price Cash Flow Ratio TTM -2.86 42.47 27.68 22.15 -15.55 -79.67
Income Statement (TTM)
ACHL NVO VRTX REGN MRNA SGEN
Revenue $0B $232.26B $9.84B $13.12B $6.75B $1.96B
Gross Profit $-0B $196.5B $8.58B $11.3B $2.06B $1.55B
Gross Profit Ratio 0% 84.6% 87.17% 86.16% 30.52% 79.1%
EBITDA $-0.08B $112.94B $3.93B $5.13B $-3.21B $-0.62B
Net Income $-0.07B $83.68B $3.62B $3.95B $-4.71B $-0.61B
EPS Diluted -1.75 18.62 13.89 34.77 -12.34 -3.3
Balance Sheet (MRQ)
ACHL NVO VRTX REGN MRNA SGEN
Long Term Debt $0B $20.53B $0.72B $2.7B $1.22B $0.04B
Total Liabilities $0.02B $207.93B $5.15B $7.11B $4.57B $0.87B
Total Equity $0.14B $106.56B $17.58B $25.97B $13.85B $2.8B
Total Investments $0B $17.5B $3.45B $13.51B $4.68B $1.42B
Total Debt $0B $27.01B $0.81B $2.7B $1.24B $0.04B
Total Assets $0.16B $314.49B $22.73B $33.08B $18.43B $3.67B
Cash Flow Statement (TTM)
ACHL NVO VRTX REGN MRNA SGEN
Net Income $-0.07B $83.68B $3.62B $3.95B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.32B $-0.27B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $108.91B $3.54B $4.59B $-3.12B $-0.45B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.78
ABCL AbCellera Biologics Inc. 3.83
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.2
ABIO ARCA biopharma, Inc. 3.47
ABOS Acumen Pharmaceuticals, Inc. 3.36
ABSI Absci Corporation 4.91
ABUS Arbutus Biopharma Corporation 2.88
ABVC ABVC BioPharma, Inc. 1.06
ABVX Abivax SA American Depositary Shares 14.09
ACAD ACADIA Pharmaceuticals Inc. 15.25
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.47
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 4.61
ACIU AC Immune SA 2.31
ACLX Arcellx, Inc. 49.74
ACRV Acrivon Therapeutics, Inc. Common Stock 8.77
ACST Acasti Pharma Inc. 2.76
ACXP Acurx Pharmaceuticals, Inc. 2.03
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 133.4
BIB ProShares Ultra Nasdaq Biotechnology 0 54.47
IBBQ Invesco Nasdaq Biotechnology ETF 0 21.69
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 6.2875
Unlock